Editas Medicine (EDIT) vs YD Bio (YDES)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Editas Medicine (EDIT) has outperformed YD Bio (YDES) over the past year, losing 30.0% versus a loss of 67.3%. Editas Medicine is the larger company by market cap ($422.3 million vs $416.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDIT | YDES |
|---|---|---|
| Share price | $2.75 | $5.88 |
| Market cap | $422.35M | $416.49M |
| 1-day change | +0.73% | -4.39% |
| YTD return | +34.15% | -51.76% |
| 1-year return | -30.03% | -67.33% |
| 5-year return | -92.77% | — |
| EPS (TTM) | $-0.68 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.33 | $22.00 |
| 52-week low | $1.66 | $1.70 |
| Distance from 52-week high | -36.49% | -73.27% |
| Analyst consensus | buy | — |
| Avg. price target upside | +114.55% | — |
| Average volume | 2.48M | 285.74K |
| Shares outstanding | 153.58M | 70.83M |
| Employees | 87 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDIT has outperformed YDES by 37.3 percentage points over the past year.
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees
About YD Bio
YDES stock →YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma.
Health Care · Medical Specialities · 13 employees
EDIT vs YDES FAQ
Which is bigger, Editas Medicine or YD Bio?
Editas Medicine (EDIT) is larger, with a market capitalization of $422.35M compared with $416.49M for YD Bio (YDES).
Which stock has performed better over the past year, EDIT or YDES?
EDIT returned -30.03% over the past 12 months, compared with -67.33% for YDES (price return, excluding dividends). Past performance does not predict future results.
Are Editas Medicine and YD Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Editas Medicine and Medical Specialities for YD Bio.